Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EBP | Q15125 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14642751 | 0.88 | ATM (0.54) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL10343404 | 0.83 | ATM (0.70) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL30869991 | 0.83 | ATM (0.70) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL17472291 | 0.81 | ATM (0.54) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL23913120 | 0.81 | ATM (0.68) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL31556187 | 0.81 | ATM (0.68) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL31556190 | 0.81 | ATM (0.68) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL1422005 | 0.80 | CALM1 (0.62) | ATMKDM4ECYP19A1MAPT | |
| SCHEMBL16641094 | 0.79 | CYP19A1 (0.77) | ATMKDM4ECA2POLBCYP19A1 | |
| SCHEMBL31157848 | 0.79 | CYP19A1 (0.77) | ATMKDM4ECA2POLBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181293-B2 | Method for the synthesis of aspalathin and analogues thereof | SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) | 2015-11-10 | — | — | US | disclosed |
| US-20130018182-A1 | Method for the Synthesis of Aspalathin and Analogues Thereof | SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018182-A1 | Method for the Synthesis of Aspalathin and Analogues Thereof | ASPH, C9, ALDH3A1 | ATM 667/4885KDM4E 550/4885CA2 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.